People · Operator
Named in public records as an officer, director or promoter · active 2011–2022 · Other Technology, Biotechnology, Business Services, Retailing, Telecommunications
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lithium Technologies, Inc. | — | Other Technology | Series C | $196.2M | $2.7B | 2011 |
| Datameer, Inc. | — | Other Technology | Series B | $97.5M | $252.8M | 2011 |
| Aminex Therapeutics, Inc. | — | Biotechnology | Series B | $34.5M | $221.4M | 2022 |
| KI Equity Holdings, LLC | — | Business Services | Series B | $18.1M | $411.4M | 2015 |
| EbLens Equity Holdings, LLC | — | Retailing | Series A | $6.2M | $31.8M | 2017 |
| Infinite Conferencing Partners, LLC | — | Telecommunications | Seed | $5.5M | $3.6M | 2015 |
| Pylum Biosciences, Inc. | — | Biotechnology | Pre-Seed | $990K | $54.7M | 2020 |
| All Across Africa | — | Retailing | Pre-Seed | $775K | $6.1M | 2019 |
| Lighthouse Social, Inc. | — | Other Technology | Pre-Seed | $410K | $12.7M | 2015 |
Jeffrey Miller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Miller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Sonsini | 1 | 18 |
| Peter Fenton | 1 | 16 |
| Ravi Mohan | 1 | 14 |
| David Martin | 1 | 13 |
| Gordon Ritter | 1 | 8 |
| Tim Miller | 1 | 8 |
| Matt Murphy | 1 | 8 |
| Kirk Bowman | 1 | 7 |
| John Walecka | 1 | 6 |
| STEPHEN MILLER | 1 | 6 |
| Jeff Miller | 1 | 4 |
| Richard Yanowitch | 1 | 4 |
| Geoffrey Moore | 1 | 4 |
| Mike Dinsdale | 1 | 3 |
| Kevin Cameron | 1 | 3 |
| Jeffrey A. Miller | 1 | 3 |
| Shawn Price | 1 | 3 |
| Doug Jones | 1 | 3 |
| Thomas Graham | 1 | 3 |
| Brooke Seawell | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.